Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
47 hedge funds and large institutions have $111M invested in Agile Therapeutics in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 7 closing their positions.
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more capital invested
Capital invested by funds: $86.5M → $111M (+$24.6M)
15% more funds holding
Funds holding: 41 → 47 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.23M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.4M |
| 4 |
DM
Deerfield Management
New York
|
+$1.02M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$814K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.66M |
| 2 |
Goldman Sachs
New York
|
-$309K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$211K |
| 4 |
ECM
Element Capital Management
New York
|
-$192K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$185K |
AGRX Hedge Fund Activity: Q3 2017 in Review
47 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q3 2017, worth a combined $111M — up 28% from $86.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AGRX positions and 7 closed out — a net gain of 7 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $3.23M. The largest seller was Invesco, exiting entirely with an estimated $4.66M sold.
- 47 institutional investors held Agile Therapeutics (AGRX) as of Q3 2017, up from 41 in Q2 2017.
- Funds reported $111M of Agile Therapeutics stock for Q3 2017, up 28% quarter-over-quarter.
- 14 funds opened new Agile Therapeutics positions in Q3 2017 and 7 closed out, a net change of +7 holders.
- The largest Agile Therapeutics buyer in Q3 2017 was Alyeska Investment Group, an estimated $3.23M added.
- The largest Agile Therapeutics seller in Q3 2017 was Invesco, an estimated $4.66M sold.
Based on aggregated 13F filings for Q3 2017.